Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

被引：13

作者：

Armando, Calogero ^{[1
]}

Evangelista, Sagnelli ^{[2
]}

Massimiliano, Creta ^{[3
]}

Silvia, Angeletti ^{[4
]}

Gaia, Peluso ^{[1
]}

Paola, Incollingo ^{[1
]}

Maria, Candida ^{[1
]}

Gianluca, Minieri ^{[1
]}

Nicola, Carlomagno ^{[1
]}

Anna, Dodaro Concetta ^{[1
]}

Massimo, Ciccozzi ^{[5
]}

Caterina, Sagnelli ^{[2
]}

机构：

[1] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, Naples, Italy

[3] Univ Naples Federico II, Dept Neurosci Human Reprod & Odontostomatol, Naples, Italy

[4] Univ Campus Biomed Rome, Unit Clin Lab Sci, Rome, Italy

[5] Univ Campus Biomed, Unit Med Stat & Mol Epidemiol, Rome, Italy

来源：

BIOMED RESEARCH INTERNATIONAL | 2019年 / 2019卷

关键词：

CHRONIC LIVER-DISEASES; HEPATITIS-C INFECTION; KIDNEY-TRANSPLANTATION; TOLERABILITY; EXPERIENCE; EFFICACY; IMPACT;

D O I：

10.1155/2019/4674560

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Hepatitis C virus (HCV) infection unfavorably affects the survival of both renal patients undergoing hemodialysis and renal transplant recipients. In this subset of patients, the effectiveness and safety of different combinations of interferon-free direct-acting antiviral agents (DAAs) have been analyzed in several small studies. Despite fragmentary, the available data demonstrate that DAA treatment is safe and effective in eradicating HCV infection, with a sustained virologic response (SVR) rates nearly 95% and without an increased risk of allograft rejection. This review article analyzes the results of most published studies on this topic to favor more in-depth knowledge of the readers on the subject. We suggest, however, perseverating in this update as the optimal DAA regimen may not be proposed yet, because of the expected arrival of newer DAAs and of the lack of data from large multicenter randomized controlled trials.

引用

收藏

页数：8

相关论文

共 105 条

[1] Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy [J].

Baid-Agrawal, Seema ;

Farris, Alton B., III ;

Pascual, Manuel ;

Mauiyyedi, Shamila ;

Farrell, Mary Lin ;

Tolkoff-Rubin, Nina ;

Collins, A. Bernard ;

Frei, Ulrich ;

Colvin, Robert B. .

KIDNEY INTERNATIONAL, 2011, 80 (08) :879-885

[2] Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women [J].

Bernabucci, Veronica ;

Ciancio, Alessia ;

Petta, Salvatore ;

Karampatou, Aimilia ;

Turco, Laura ;

Strona, Silvia ;

Critelli, Rosina ;

Todesca, Paola ;

Cerami, Caterina ;

Sagnelli, Caterina ;

Rizzetto, Mario ;

Camma, Calogero ;

Villa, Erica .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (44) :16726-16733

[3] Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study [J].

Bhamidimarri, Kalyan R. ;

Ladino, Marco ;

Pedraza, Fernando ;

Guerra, Giselle ;

Mattiazzi, Adela ;

Chen, Linda ;

Ciancio, Gaetano ;

Kupin, Warren ;

Martin, Paul ;

Burke, George ;

Roth, David .

TRANSPLANT INTERNATIONAL, 2017, 30 (09) :865-873

[4] Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus [J].

Bloom, RD ;

Rao, V ;

Weng, F ;

Grossman, RA ;

Cohen, D ;

Mange, KC .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05) :1374-1380

[5] Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation [J].

Bruchfeld, A ;

Wilczek, H ;

Elinder, CG .

TRANSPLANTATION, 2004, 78 (05) :745-750

[6] Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial [J].

Bruchfeld, Annette ;

Roth, David ;

Martin, Paul ;

Nelson, David R. ;

Pol, Stanislas ;

Londono, Maria-Carlota ;

Monsour, Howard, Jr. ;

Silva, Marcelo ;

Hwang, Peggy ;

Arduino, Jean-Marie ;

Robertson, Michael ;

Bach-Yen Nguyen ;

Wahl, Janice ;

Barr, Eliav ;

Greaves, Wayne .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08) :585-594

[7] Hepatitis C Virus and Nonliver Solid Organ Transplantation [J].

Carbone, Marco ;

Mutimer, David ;

Neuberger, James .

TRANSPLANTATION, 2013, 95 (06) :779-786

[8] Total colectomy for cancer: Analysis of factors linked to patients' age [J].

Carlomagno, Nicola ;

Santangelo, Michele L. ;

Amato, Bruno ;

Calogero, Armando ;

Saracco, Michele ;

Cremone, Cristiano ;

Miranda, Agnese ;

Dodaro, Concetta ;

Renda, Andrea .

INTERNATIONAL JOURNAL OF SURGERY, 2014, 12 :S135-S139

[9] Rare multiple primary malignancies among surgical patients-a single surgical unit experience [J].

Carlomagno, Nicola ;

Santangelo, Michele L. ;

Mastromarino, Rossella ;

Calogero, Armando ;

Dodaro, Concetta ;

Renda, Andrea .

ECANCERMEDICALSCIENCE, 2014, 8

[10] Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection A PRISMA-compliant study [J].

Chen, Keliang ;

Lu, Pei ;

Song, Rijin ;

Zhang, Jiexiu ;

Tao, Rongzhen ;

Wang, Zijie ;

Zhang, Wei ;

Gu, Min .

MEDICINE, 2017, 96 (30)

← 1 2 3 4 5 6 7 8 9 10 →